Long-Term Vitamin K Antagonists and Cancer Risk

  title={Long-Term Vitamin K Antagonists and Cancer Risk},
  author={M. Shurrab and K. Quinn and A. Kitchlu and C. Jackevicius and D. Ko},
  journal={American Journal of Clinical Oncology},
  pages={717 - 724}
Supplemental Digital Content is available in the text. Objectives: Vitamin K antagonists (VKAs) remain one of the most commonly used anticoagulation therapies. The potential anticancer effect of long-term use of VKAs has been a matter of debate with conflicting results. Our goal was to perform a systematic review and meta-analysis examining the association between long-term VKAs use and cancer risk. Methods: Systematic searches of multiple major databases were performed from inception until… Expand
Vitamin K intake and breast cancer incidence and death: results from a prospective cohort study.
The present study suggests that total MK intake was associated with an altered risk of the occurrence and death of breast cancer in the general US population, and reducing dietary intake of menaquinones may offer a novel strategy for breast cancer prevention. Expand
Natural Disasters in the Americas, Dialysis Patients, and Implications for Emergency Planning: A Systematic Review
This systematic review is the first study that presents a synthesis of the scientific literature on the effects of disasters on dialysis populations and highlighted the need for predisaster interventions at the patient and health care system levels. Expand
  • 2018


Long-term use of vitamin K antagonists and incidence of cancer: a population-based study.
The hypothesis that anticoagulation might have a protective effect on cancer development, especially prostate cancer, is supported in a population-based study including all cancer- and thromboembolism-free patients of a health area. Expand
Cancer risk in long‐term users of vitamin K antagonists: A population‐based case–control study
The authors' study does not support a general chemopreventive effect of VKA drugs, however, in accordance with findings from previous studies, it found an inverse association between use of Vka and prostate cancer. Expand
Warfarin use and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer
This study, which included a larger number of PCa cases with warfarin exposure than previous studies, does not support previous notions of decreased risk of PCan users, and no difference in risk was found between war Farfarin and other anticoagulants. Expand
The effect of anticoagulants on cancer risk and survival: systematic review.
Clinical evidence exists in support of an anti-neoplastic effect of anticoagulants, however, more research is needed to further define which cancer type and stage would most benefit from low molecular weight heparin, as well as to explore the role of warfarin in urogenital tumour development. Expand
The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable.
The authors examined the associations between VKA therapy and incidence of 24 site-specific cancers with a Danish population-based cohort study, using heart valve replacement as an instrumental variable and results do not support the existing hypothesis that VKA Therapy is associated with reduced cancer risk. Expand
Cancer prevention and vitamin K antagonists: an overview.
Most studies show that there is benefit from the addition of warfarin to chemotherapy in the tumour development, expansion and on the patient survival, especially in particular types of cancers, however, they call for efforts in preparing large scale randomized trials to elucidate the effect of anticoagulation in the setting of neoplastic disease. Expand
Association of Warfarin Use With Lower Overall Cancer Incidence Among Patients Older Than 50 Years
Warfarin use may have broad anticancer potential in a large, population-based cohort of persons older than 50 years, and this finding could have important implications for the selection of medications for patients needing anticoagulation. Expand
Does warfarin therapy influence the risk of bladder cancer?
The results suggest that warfarin does not protect against bladder cancer, at least in male smokers, the highest risk population for bladder cancer. Expand
Use of oral anticoagulants and risk of prostate cancer: a population-based case–control study in Montreal, Canada
These findings provide weak support for a protective effect of oral anticoagulant therapy against prostate cancer, and further confirmation is required, especially in light of potential bleeding complications associated with antICOagulants. Expand
Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study.
The results suggest that warfarin has an antitumour effect that is specific to prostate cancer, and further investigation, with more complete assessment of confounders and that addresses the effect of warFarin on mortality of prostate cancer is warranted. Expand